UNITED THERAPEUTICS Corp reported the quarter ended March 31, 2026 results: revenue $781.5, net income $274.9, EPS $5.82.
“First Quarter 2026 Financial Results Key financial highlights include (dollars in millions, except per share data): Three Months Ended March 31, Dollar Change Percentage Change 2026 2025 Total revenues $ 781.5 $ 794.4 $ (12.9) (2) % Net income $ 274.9 $ 322.2 $ (47.3) (15) % Net income, per basic share $ 6.32 $ 7.18 $ (0.86) (12) % Net income, per diluted share $ 5.82 $ 6.63 $ (0.81) (12) %”
Material Agreements
UNITED THERAPEUTICS Corp entered into Collared Accelerated Share Repurchase Agreement with Citibank, N.A. valued at $750,000,000 (effective 2026-03-09).
“Under the Collared ASR, which is being entered into pursuant to the Master Confirmation between the Company and Citi, dated August 1, 2025, the Company will receive an initial delivery of approximately 708,657 shares of Common Stock on March 11, 2026 representing approximately 50% of the total shares that would be repurchased under the Collared ASR (the Initial Delivery Amount ), measured based on the closing price of the Common Stock on March 9, 2026.”
Material Agreements
UNITED THERAPEUTICS Corp entered into Uncollared Accelerated Share Repurchase Agreement with Citibank, N.A. valued at $750,000,000 (effective 2026-03-09).
“Under the Uncollared ASR, which is being entered into pursuant to the Master Confirmation between the Company and Citi, dated March 25, 2024, the Company will receive an initial delivery of approximately 992,120 shares of Common Stock on March 11, 2026 representing approximately 70% of the total shares that would be repurchased under the Uncollared ASR, measured based on the closing price of the Common Stock on March 9, 2026.”
Governance Changes
UNITED THERAPEUTICS Corp: Amended and restated bylaws to implement cure process for director nomination deficiencies, remove language allowing board to require supermajority vote, and lower stockholder vote required to amend bylaws from 80% to majority of voting power (effective 2026-01-21).
“On January 21, 2026, the Board also approved amendments to, and the restatement of, the Company’s Tenth Amended and Restated Bylaws.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.